Home/Pipeline/Ischemic Stroke Program

Ischemic Stroke Program

Ischemic Stroke

Pre-clinicalActive

Key Facts

Indication

Ischemic Stroke

Phase

Pre-clinical

Status

Active

Company

CHS Pharma

About CHS Pharma

CHS Pharma is a private, preclinical-stage biotech company targeting multi-billion dollar markets in neurology, ophthalmology, and dermatology with novel small molecule therapies. The company highlights programs aimed at reversing the effects of ischemic stroke and mitigating dry macular degeneration, positioning itself for strategic partnerships and investment. While demonstrating scientific activity through publications and intellectual property, the company appears to be in an early development phase with a lean operational structure.

View full company profile

Therapeutic Areas

Neurology Ophthalmology Dermatology

Other Ischemic Stroke Drugs

Drug	Company	Phase	Status
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Phase 3	Active (US trials with FDA orphan drug designation)
MultiStem	Athersys	Phase 3	Active (subject to funding)
IQool™ System	BrainCool	Clinical Evaluation	Evidence Generation
itMSCs + itNSCs	Stemedica Cell Technologies	Research	Active
BXT-25	BioXyTran	Preclinical	Active
3K3A-APC	ZZ Biotech	Phase 2/3	Active
Ischemic Stroke Device(s)	Infinity Neuro	Pre-clinical	Active
THDG3	DeckTherapeutics	Pre-clinical	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active
iNstroke Catheters	iVascularU	Commercial	Active
Dual Thrombolytic Regimen (tPA + HisproUK)	Thrombolytic Science International	Phase 2	Active
Neural Stem Cell Therapy for Stroke	Neoneuron	Pre-clinical	Active